Tirzepatide: reported timelines in the literature
A research-supply review of reported timelines for tirzepatide (LY3298176) across clinical studies, from 60-day preoperative windows to 12-month treatment periods. For laboratory research use only.
Tirzepatide, also known as LY3298176, is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor families. The evidence block for this page does not provide sequence, formula, or molecular weight identifiers; those are not reported here. In the studies summarised below, reported timelines range from a 60-day preoperative medication window [1] to a 12-month treatment period [5], with several trials reporting primary endpoints at approximately 6 months [3] or 1 year [1].
The work centres on the GIP and GLP-1 receptor families, as stated in the postbariatric hypoglycemia case series [6].
Research Studies
Tirzepatide and preoperative optimisation before one anastomosis gastric bypass
A registered clinical trial compares three preoperative strategies before one anastomosis gastric bypass (OAGB) for severe obesity: tirzepatide medication for 60 days, a ketogenic diet for 4 weeks, or standard care [1]. The main goal is to determine which approach leads to the best weight loss one year after surgery. The study will also evaluate safety, surgical outcomes, and improvement of obesity-related health conditions such as diabetes, high blood pressure, and sleep apnea [1]. The reported timeline for the medication arm is 60 days, with the primary outcome assessed at one year.
Tirzepatide and progestin intrauterine device in endometrial hyperplasia and grade 1 endometrial cancer
A phase II trial studies whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response (absence of cancer cells in tissue samples after treatment) in women with endometrial atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) or grade 1 endometrial cancer who are overweight or obese [2]. The evidence block does not specify the treatment duration or the timing of the primary endpoint for this trial. The study notes that endometrial cancer occurrence has continued to rise in the United States, and that over half of endometrial cancer cases are thought to be attributable to being overweight and obese, with a risk relationship that appears to be weight dependent [2].
Tirzepatide and levonorgestrel IUD therapy for EIN and early-stage endometrial cancer
A single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard levonorgestrel intrauterine device (LNG-IUD) therapy in patients with endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid endometrial carcinoma with co-existing obesity and metabolic risk factors [3]. Participants will receive tirzepatide once weekly while continuing standard clinical management with an LNG-IUD. Treatment decisions remain at the discretion of the treating physician. The primary objective is to evaluate pathologic response at approximately 6 months. Secondary objectives include changes in metabolic parameters and assessing the incidence of adverse events [3].
Tirzepatide and real-world outcomes in Pakistani adults with obesity, prediabetes, and type 2 diabetes
A multicentre, prospective, observational study examines tirzepatide as used in routine clinical care in Pakistan [4]. Tirzepatide is already approved for type 2 diabetes and for obesity, but there is very little information on how it works for people in South Asia, and none from Pakistan specifically [4]. The study will follow 330 adults who are starting tirzepatide as part of their normal treatment, across ten diabetes and endocrinology centres in Pakistan. Everyone taking part has obesity, and they are grouped into three cohorts based on their blood sugar status at the start: obesity without diabetes, prediabetes with obesity, and type 2 diabetes [4]. The evidence block does not report the follow-up duration for this observational study.
Tirzepatide and central centrifugal cicatricial alopecia
A pilot clinical trial aims to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults [5]. The main questions are whether tirzepatide improves the symptoms and signs of active CCCA, whether it changes the activity of genes in the scalp, especially genes related to scarring, and whether it promotes hair regrowth [5]. Participants will inject tirzepatide once a week for 12 months, visit the clinic for scalp examinations, photographs, and other health assessments, and have scalp biopsies at the beginning of the study and after 6 months of treatment, along with blood tests [5]. The reported timeline is a 12-month treatment period with a 6-month biopsy timepoint.
Tirzepatide and postbariatric hypoglycemia after Roux-en-Y gastric bypass
A case series describes 3 patients with postbariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass who were treated with tirzepatide, a GLP-1 and GIP receptor agonist [6]. All patients presented with symptomatic hypoglycemia characterised by episodes of diaphoresis, visual disturbances, confusion, and documented low blood glucose levels occurring postprandially. Conventional management strategies, including dietary modifications, acarbose, and other pharmacotherapies, were either partially effective or limited by side effects [6]. The evidence block does not report the duration of tirzepatide treatment or the follow-up interval for these cases.
Tirzepatide and ileal pouch-anal anastomosis with chronic high bowel frequency
A clinical trial aims to learn if tirzepatide (Zepbound) can decrease bowel frequency in patients who have an ileal-pouch anal anastomosis (IPAA or pouch) better than standard of care anti-diarrheal therapy [7]. The main question is whether tirzepatide reduces bowel frequency better than standard of care anti-diarrheal therapy in patients that have a pouch. Participants will visit the clinic 5 times, answer questions about symptoms daily, be assigned to take the study product as instructed, and provide a stool sample 4 times [7]. The evidence block does not specify the treatment duration or the timing of the primary endpoint.
Tirzepatide and stomach emptying in type 1 diabetes with overweight or obesity
A study of tirzepatide (LY3298176) in participants with type 1 diabetes mellitus (T1DM) and overweight or obesity aims to learn more about how tirzepatide affects stomach emptying [8]. Participation in this study will last about 8 weeks, including screening and follow-up [8]. The reported timeline is approximately 8 weeks.
Tirzepatide and reported timelines across study types
The table below compares the reported timelines and primary endpoint timepoints across the studies in the evidence block. Where the evidence block does not report a duration or timepoint, the cell is marked as not reported.
| Study | Population | Reported treatment duration | Primary endpoint timepoint |
|---|---|---|---|
| Preoperative optimisation before OAGB [1] | Adults with severe obesity undergoing OAGB | 60 days (medication arm) | 1 year after surgery |
| LNG-IUD plus tirzepatide in AH/EIN or grade 1 endometrial cancer [2] | Women with AH/EIN or grade 1 endometrial cancer who are overweight or obese | Not reported | Not reported |
| Tirzepatide plus LNG-IUD in EIN or grade 1 endometrioid carcinoma [3] | Patients with EIN or grade 1 endometrioid endometrial carcinoma with obesity and metabolic risk factors | Once weekly; duration not reported | Approximately 6 months |
| Real-world outcomes in Pakistani adults [4] | 330 adults with obesity, prediabetes, or type 2 diabetes | Not reported | Not reported |
| CCCA pilot trial [5] | Adults with active CCCA | 12 months | Not reported; scalp biopsy at 6 months |
| PBH case series [6] | 3 patients with PBH after Roux-en-Y gastric bypass | Not reported | Not reported |
| IPAA and chronic high bowel frequency [7] | Patients with an ileal-pouch anal anastomosis | Not reported | Not reported |
| Stomach emptying in T1DM with overweight or obesity [8] | Participants with T1DM and overweight or obesity | About 8 weeks (including screening and follow-up) | Not reported |
Across the evidence block, the shortest reported timeline is the 60-day preoperative medication window [1], and the longest reported treatment period is 12 months [5]. One study reports a primary endpoint at approximately 6 months [3], and another reports a primary outcome at one year after surgery [1]. Several studies do not report a treatment duration or endpoint timepoint in the evidence block [2][4][6][7].
Reference-only items in the evidence block include a commentary on oral health implications for oral medicine practice [9], a report on adults with early uncontrolled type 2 diabetes comparing tirzepatide with intensified conventional care over 2 years [10], a reconstructed aggregate-data Bayesian longitudinal meta-analysis of weight regain trajectories after discontinuation of semaglutide or tirzepatide [11], and a comment on comparative effectiveness of tirzepatide versus dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes and cardiovascular disease [12]. These items support the page but are not its content; their findings are reported here in summary form only.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery
- [2] A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
- [3] Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer
- [4] Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes
- [5] Tirzepatide for Treatment of CCCA
- [6] Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.
- [7] Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
- [8] A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
- [9] Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice.
- [10] In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y.
- [11] Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
- [12] Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.